Phospholipogenic Pharmaceuticals Are Associated with a Higher Incidence of Histological Findings than Nonphospholipogenic Pharmaceuticals in Preclinical Toxicology Studies
While phospholipidosis is thought to be an adaptive response to chemical challenge, many phospholipogenic compounds are known to display adverse effects in preclinical species and humans. To investigate the link between phospholipogenic administration and incidence of preclinical histological signal...
Saved in:
Main Authors: | Linda R. Barone, Scott Boyer, James R. Damewood, James Fikes, Paul J. Ciaccio |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Journal of Toxicology |
Online Access: | http://dx.doi.org/10.1155/2012/308594 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Differential Cytotoxicity Responses by Dog and Rat Hepatocytes to Phospholipogenic Treatments
by: James K. Morelli, et al.
Published: (2013-01-01) -
Chemical, Spectral, Biological, and Toxicological Studies of Some Benzene Derivatives Used in Pharmaceuticals: In Silico Approach
by: Emranul Kabir, et al.
Published: (2024-12-01) -
Nutraceuticals and Pharmaceuticals
by: E. A. Poluektova, et al.
Published: (2020-05-01) -
PretoxTM: a text mining system for extracting treatment-related findings from preclinical toxicology reports
by: Javier Corvi, et al.
Published: (2025-02-01) -
PHARMACEUTICAL GELS
by: Syeda Yamna Zia
Published: (2024-10-01)